Peer-reviewed article
Prognostic factors and clinical outcomes in pediatric Langerhans Cell Histiocytosis: a retrospective cohort study on event-free survival.
Kang Wang, Chen Wang, Hua Zhu, Yan Zou, Yiren Tian et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a medical study examining prognostic factors for a rare pediatric cancer called Langerhans Cell Histiocytosis. The researchers analyzed 67 children treated in China and found that elevated white blood cell counts and disease affecting multiple body sites predicted worse survival outcomes. The study aims to help doctors better identify which children need more intensive treatment.
Key points
- 3-year event-free survival rate was 76.1% in the cohort of 67 pediatric LCH patients
- Elevated initial WBC count (>10 × 10⁹/L) independently predicted shorter event-free survival (HR = 2.89, p = 0.034)
- Multiple site disease involvement independently predicted shorter EFS (HR = 3.12, p = 0.025)
- Risk-organ involvement, traditionally used for stratification, was not an independent predictor in multivariate analysis
- Systemic inflammatory burden reflected by leukocytosis offers independent prognostic value
Limitations
This is a retrospective cohort study from a single hospital in China, limiting generalizability. The sample size of 67 patients is relatively small, and the study cannot establish causation or compare treatment approaches.
Abstract
OBJECTIVES: Langerhans Cell Histiocytosis (LCH) is an inflammatory myeloid neoplasm with heterogeneous outcomes. This study aimed to identify independent risk factors influencing event-free survival (EFS) in pediatric LCH, focusing on initial white blood cell (WBC) counts and disease extent. METHODS: We retrospectively analyzed 67 pediatric LCH patients with bone involvement treated at Hebei Children's Hospital, Hebei Clinical Medicine Research Center for Children's Health and Diseases between 2013 and 2022. The primary endpoint was EFS. Cox proportional hazards regression models determined predictors of adverse outcomes. RESULTS: The 3-year EFS rate was 76.1% (median follow-up: 48 months). Univariate analysis linked multiple disease sites, risk-organ involvement, CNS risk site involvement, diabetes insipidus, and elevated WBC count to poor EFS. In multivariate analysis, only multiple site involvement (Hazard Ratio [HR] = 3.12, p = 0.025) and an elevated initial WBC count (>10 × 10⁹/L) (HR = 2.89, p = 0.034) remained independent predictors. DISCUSSION: While risk-organ involvement is a traditional stratifier, systemic inflammatory burden, reflected by leukocytosis, offers independent prognostic value. Patients with elevated WBC counts or multisite disease warrant intensive monitoring. CONCLUSION: Elevated initial WBC count and multiple site involvement independently predict shorter EFS in pediatric LCH. Integrating these markers into risk stratification could optimize therapies.